Shilpa Medicare receives Import Alert for its Telangana facility
Three products exempted from Import Alert
Shilpa Medicare has received an Import Alert 66-40 on 17 February 2021, pursuant to the USFDA inspection of the Unit 4, Jadcherla, Telangana facility from 13 February to 20 February and 24 February to 25 February 2020.The company announced that three products have been exempted from the Import Alert - Azacitidine for Injection, Cyclophosphamide Capsules and Erlotinib Tablets
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content